신경 재생 : 예측 바이오마커로부터 뇌 수복까지

The report describes how predictive biomarkers are changing the global landscape of neuroregeneration and transitioning from the concept of control of brain injury to an active repair of the brain. This report describes how brain injuries from scans were being replaced by blood tests being developed to measure the burden of Alzheimer's disease, measure the presence of brain injury after an acute brain injury (e.g., as a result of a stroke), and measure early nerve fiber damage that will happen for years before the first symptoms of various diseases such as multiple sclerosis, ALS, and dementia occur. Furthermore, this report describes the various types of biomarkers that comprise an integrated approach to the measurement of brain function and health, describes how biomarkers are being used to categorize patients, time interventions to windows of opportunity for repair, and use pharmacodynamic biomarker data as an indication of what drugs will repair the brain, and serve as an indication of how long the brain will take to recover from injuries. The report describes four major methods used in human studies to develop brain repair therapies in cell replacement; pharmacologic treatments that neutralize chemicals that inhibit the formation of scar tissue; partial resetting of aging through gene therapy; and closed loop neuromodulation to restore standing and stepping ability to subjects with chronic paralysis. The report also highlights the linkage of various advances in biomarkers and therapies to changes in competition and creative partnerships among key participants in the industry, including pharmaceutical companies, diagnostic laboratories, medtech developers, and artificial intelligence firms; and to new business models that will combine diagnostic tests, therapeutic delivery systems and the delivery of data services to create complete outcomes based solutions for patients with neurodegenerative disorders.

Table of Contents

Strategic Evolution of Biomarker Technologies

• Global Burden of Brain Disease and Injury
• Limits of Spontaneous Regeneration of Brains and Neurons
• From Neuroprotection and Neurorestoration to Neuroregeneration
• Biomarkers and Brain-Repair Strategies
• Biochemical Biomarkers
• Molecular Biomarkers
• Imaging Biomarkers

Key Companies Driving Innovation Across Brain Disease and Neurorepair Biomarkers

• Leading Innovators in Biomarkers for Brain Disease and Repair

Funding, Partnerships, & Acquisitions

• Funding Architecture
• Brain Repair: Investment
• Strategic Partnerships & Initiatives Advancing Brain Repair

Outlook - Future Directions and Prospects

• Biochemical Biomarkers: Fluid-Based Dynamics & Re-Engineering
• Molecular Biomarkers: Genetic Reprogramming & Transcriptomic
• Imaging Biomarkers: Macroscopic Brain Topology & Synaptic Reconnection

Growth Opportunity Universe

• Growth Opportunity 1: Liquid Biopsy Multi-Omics for Real-Time Treatment Calibration
• Growth Opportunity 2: Directed In Vivo Glial Reprogramming via Programmed Nucleic Acid Vectors
• Growth Opportunity 3: Digital Twin Connectomics and Synaptic Radiotracers for Circuit Verification

Next Steps

• Benefits and Impacts of Growth Opportunities
• Next Steps
• Legal Disclaimer